Phosphonate quinoxalinedione AMPA antagonists

Restorative Neurology and Neuroscience

Volumn 17, Issue 1, 2000, Pages 45-59

  Turski, L ^a   Schneider, H H ^a   Neuhaus, R ^a   McDonald, F ^a   Jones, G H ^a   Lofberg, B ^a   Schweinfurth, H ^a   Huth, A ^a   Kruger, M ^a   Ottow, E ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Analgesia; Anxiety; Glutamate antagonists; Muscle tone; Neuroprotection; Seizures; Stroke; Traumatic brain injury

Indexed keywords

[[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GLUTAMATE RECEPTOR ANTAGONIST; PHOSPHONATE QUINOXALINE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; ZK 202000;

ANALGESIA; ANIMAL CELL; ANXIETY NEUROSIS; BRAIN INJURY; MIDDLE CEREBRAL ARTERY OCCLUSION; MUSCLE TONE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEIZURE; STROKE;

EID: 0033766040     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans
2. Finding new drugs to treat stroke
3. Mechanisms of excitotoxicity in neurologic disease
4. Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline
5. AMPA receptor antagonists and local cerebral glucose utilization in the rat
6. Do NMDA antagonists protect against cerebral ischemia: Are clinical trials warranted?
7. AMPA antagonists: Do they hold more promise for clinical stroke trials than NMDA antagonists?
8. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats
9. Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia
10. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat
11. Massive persistent release of excitatory amino acids following human occlusive stroke
12. 3H]-dichlorokynurenic acid
13. Intravenous NBQX inhibits spontaneously occurring sympathetic nerve activity and reduces blood pressure in cats
14. Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital
15. Duration of glutamate release after acute ischemic stroke
16. Structure-activity relationship in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-Dichloro-(1H)-oxoquinoline-3-]phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties
17. Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX
18. Combined blockade of NMDA and non-NMDA receptors produces respiratory arrest in the adultcat
19. The neuroprotective effects of the decahydroisoquinoline, LY215490, a novel AMPA antagonist in focal ischaemia
20. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischemia model
21. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches
22. Cloned glutamate receptors
23. 3H-CNQX binds with equal affinity to two agonist states of quisqualate receptors
24. 3H-kainate binding sites with different molecular target sizes in rat cortex
25. Chaotropic ions affect the conformation of quisqualate receptors in rat cortical membranes
26. Neurodegenerative disorders: Clues from glutamate and energy metabolism
27. Pharmacology of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline
28. Therapeutic approaches to neurologic disorders with excitatory amino acid antagonists
29. Neuroprotective effect of YM90K, an AMPA-receptor antagonist, against delayed neuronal death induced by transient global cerebral ischemia in gerbils and rats
30. Post-ischemic treatment with S 17625-2, a new AMPA receptor antagonist, protects the rat brain after permanent focal ischemia
31. The non-NMDA antagonists, NBQX and GYKI52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat
32. Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury
33. Over-additive protective effect of dizocilpine and NBQX against neuronal damage
34. N-Methyl-D-aspartic acid receptor structure and function
35. AMPA receptor competitive antagonism reduces halothane MAC in rats
36. Potentiation of MK-801-induced breathing impairment by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline
37. Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia
38. Excitotoxic mechanisms operative in youth and old age
39. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
40. 3H]-D-AP5 binding sites in rat brain membranes
41. 3H CPP, a new competitive ligand for NMDA receptors
42. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
43. NMDA and non-NMDA receptors may play distinct roles in timing mechanisms and transmission in the feline respiratory network
44. Alprazolam dependence prevented by substituting with the β-carboline abecarnil
45. Pathophysiology of acute ischemic stroke
46. New treatments for acute stroke
47. Delayed treatment with the novel AMPA receptor antagonist, PD152247 (PNQX), reduces lesion size following focal ischemia and reperfusion in the rat
48. The triggering of spreading depression in the chicken retina
49. 2, 3-Dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline: A neuroprotectant for cerebral ischemia
50. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischemia, even when delayed 24 h
51. YM90K: Pharmacological characterization as a selective and potent α-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist
52. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat
53. β-Carbolines can enhance or antagonise the effects of punishment in mice
54. 3H]TCP) to the NMDA-phencyclidine receptor complex
55. Diazepam dependence prevented by glutamate antagonists
56. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX)
57. Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbral region following middle cerebral artery occlusion in the rat: Correlation with histopathology
58. N-Methyl-D-aspartate receptor complex: Different sites for regulation and clinical consequences
59. + neurotoxicity by N-methyl-D-aspartate antagonists
60. ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma
61. Glutamate, energy metabolism and neuropathology: Relevance to neurodegenerative disorders
62. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline
63. Effect of kainic acid on body temperature in rats
64. Structure-activity relationship in the development of excitatory amino acid receptor agonists and competitive antagonists
65. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction
66. Effects of a novel AMPA antagonist YM900 and other excitatory amino acid antagonists on the delayed neuronal death in the gerbil hippocampus